Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 24, 2025
Subject: Regulatory approval of Blenrep (belantamab mafodotin) combinations in the European Union (EU) for the treatment of relapsed or refractory multiple myeloma.
Key Financial Metrics
This filing is a regulatory announcement regarding clinical trial results and product approvals. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics.
Material Changes and Clinical Results
The filing details the EU approval of Blenrep based on superior efficacy in two Phase III trials (DREAMM-7 and DREAMM-8) compared to standard of care:
- DREAMM-7 Trial (Blenrep + Bortezomib + Dexamethasone vs. Daratumumab-based triplet):
- Progression-Free Survival (PFS): Median PFS was 36.6 months for Blenrep vs. 13.4 months for comparator (Hazard Ratio [HR]: 0.41; p<0.00001).
- Overall Survival (OS): 42% reduction in risk of death (HR: 0.58; p=0.00023). Three-year OS rate was 74% (Blenrep) vs. 60% (comparator).
- DREAMM-8 Trial (Blenrep + Pomalidomide + Dexamethasone vs. Bortezomib-based triplet):
- Progression-Free Survival (PFS): Median PFS not yet reached for Blenrep vs. 12.7 months for comparator at primary analysis.
- Safety Profile: Eye-related side effects were manageable with dose modifications (discontinuation rate ≤9%). Common non-ocular adverse events included thrombocytopenia, neutropenia, and diarrhea.
Outlook, Management Commentary, and Risks
Management Commentary: GSK leadership describes the approval as a "redefining moment" for multiple myeloma treatment in the EU, noting the potential to extend remission and survival from the first relapse. The drug offers a differentiated mechanism of action (anti-BCMA ADC) and can be administered in community-based settings.
Regulatory Outlook: Blenrep combinations are already approved in the UK, Japan, Canada, and Switzerland. Applications are under review in major global markets, including the US (Breakthrough Therapy Designation and Priority Review) and China (Priority Review).
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ due to risks described in GSK's 2024 Form 20-F and Q1 2025 results, including regulatory uncertainties and clinical trial outcomes.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for Blenrep in the EU following the July 2025 approval.
- Monitor the status of pending regulatory applications in the US (FDA) and China (NMPA) for potential approval dates.
- Review GSK's upcoming quarterly earnings reports for revenue recognition related to Blenrep sales in newly approved markets.
- Assess the competitive landscape for anti-BCMA therapies and the potential impact on GSK's oncology portfolio margins.
- Confirm the long-term safety data regarding eye-related adverse events as post-marketing surveillance continues.